Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma

Giuseppe Procopio, Elena Verzoni, Arpine Gevorgyan, Maddalena Mancin, Sara Pusceddu, Laura Catena, Marco Platania, Valentina Guadalupi, Antonia Martinetti, Emilio Bajetta

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: The aim of our study was to evaluate the efficacy and safety in unresectable or advanced renal carcinoma treated with sorafenib, in a situation closely similar to the everyday medical practice. Patients and Methods: One hundred and thirty-six patients have been treated with 400 mg b.i.d. of sorafenib administered orally until disease progression or unacceptable toxicity. They were either previously untreated or relapsed after one or more previous treatments with systemic therapy. Most of them had clear cell renal carcinoma (RCC), but other histological types such as papillary, chromophobe, Bellini ducts, sarcomatoid and mixed forms were also represented. Results: Overall disease control of 70.6% was achieved with 7.9% of partial remissions. Response was observed in the majority of patients with RCC, but also in some patients with non-clear cell RCC. Safety was acceptable, with the most common adverse events consisting of hand-foot skin reaction, cutaneous rash, diarrhoea, fatigue and hypertension. Conclusions: The results confirm previous ones reported in the literature concerning the efficacy and the safety of sorafenib as second-line treatment in patients with RCC. In addition, they disclose the hypothesis that sorafenib could be effective also in patients who underwent multiple previous treatments and in those with histology different from clear cells.

Original languageEnglish
Pages (from-to)204-209
Number of pages6
JournalOncology
Volume73
Issue number3-4
DOIs
Publication statusPublished - Apr 2008

Fingerprint

Renal Cell Carcinoma
Safety
Carcinoma
Kidney
Therapeutics
Exanthema
Fatigue
Disease Progression
sorafenib
Foot
Diarrhea
Histology
Hand
Hypertension
Skin

Keywords

  • Drug-related toxicity
  • Multikinase inhibitor
  • Renal cell cancer
  • Sorafenib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. / Procopio, Giuseppe; Verzoni, Elena; Gevorgyan, Arpine; Mancin, Maddalena; Pusceddu, Sara; Catena, Laura; Platania, Marco; Guadalupi, Valentina; Martinetti, Antonia; Bajetta, Emilio.

In: Oncology, Vol. 73, No. 3-4, 04.2008, p. 204-209.

Research output: Contribution to journalArticle

Procopio, Giuseppe ; Verzoni, Elena ; Gevorgyan, Arpine ; Mancin, Maddalena ; Pusceddu, Sara ; Catena, Laura ; Platania, Marco ; Guadalupi, Valentina ; Martinetti, Antonia ; Bajetta, Emilio. / Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. In: Oncology. 2008 ; Vol. 73, No. 3-4. pp. 204-209.
@article{0f408c77c20d410a823fc768554c9d53,
title = "Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma",
abstract = "Background: The aim of our study was to evaluate the efficacy and safety in unresectable or advanced renal carcinoma treated with sorafenib, in a situation closely similar to the everyday medical practice. Patients and Methods: One hundred and thirty-six patients have been treated with 400 mg b.i.d. of sorafenib administered orally until disease progression or unacceptable toxicity. They were either previously untreated or relapsed after one or more previous treatments with systemic therapy. Most of them had clear cell renal carcinoma (RCC), but other histological types such as papillary, chromophobe, Bellini ducts, sarcomatoid and mixed forms were also represented. Results: Overall disease control of 70.6{\%} was achieved with 7.9{\%} of partial remissions. Response was observed in the majority of patients with RCC, but also in some patients with non-clear cell RCC. Safety was acceptable, with the most common adverse events consisting of hand-foot skin reaction, cutaneous rash, diarrhoea, fatigue and hypertension. Conclusions: The results confirm previous ones reported in the literature concerning the efficacy and the safety of sorafenib as second-line treatment in patients with RCC. In addition, they disclose the hypothesis that sorafenib could be effective also in patients who underwent multiple previous treatments and in those with histology different from clear cells.",
keywords = "Drug-related toxicity, Multikinase inhibitor, Renal cell cancer, Sorafenib",
author = "Giuseppe Procopio and Elena Verzoni and Arpine Gevorgyan and Maddalena Mancin and Sara Pusceddu and Laura Catena and Marco Platania and Valentina Guadalupi and Antonia Martinetti and Emilio Bajetta",
year = "2008",
month = "4",
doi = "10.1159/000127387",
language = "English",
volume = "73",
pages = "204--209",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3-4",

}

TY - JOUR

T1 - Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma

AU - Procopio, Giuseppe

AU - Verzoni, Elena

AU - Gevorgyan, Arpine

AU - Mancin, Maddalena

AU - Pusceddu, Sara

AU - Catena, Laura

AU - Platania, Marco

AU - Guadalupi, Valentina

AU - Martinetti, Antonia

AU - Bajetta, Emilio

PY - 2008/4

Y1 - 2008/4

N2 - Background: The aim of our study was to evaluate the efficacy and safety in unresectable or advanced renal carcinoma treated with sorafenib, in a situation closely similar to the everyday medical practice. Patients and Methods: One hundred and thirty-six patients have been treated with 400 mg b.i.d. of sorafenib administered orally until disease progression or unacceptable toxicity. They were either previously untreated or relapsed after one or more previous treatments with systemic therapy. Most of them had clear cell renal carcinoma (RCC), but other histological types such as papillary, chromophobe, Bellini ducts, sarcomatoid and mixed forms were also represented. Results: Overall disease control of 70.6% was achieved with 7.9% of partial remissions. Response was observed in the majority of patients with RCC, but also in some patients with non-clear cell RCC. Safety was acceptable, with the most common adverse events consisting of hand-foot skin reaction, cutaneous rash, diarrhoea, fatigue and hypertension. Conclusions: The results confirm previous ones reported in the literature concerning the efficacy and the safety of sorafenib as second-line treatment in patients with RCC. In addition, they disclose the hypothesis that sorafenib could be effective also in patients who underwent multiple previous treatments and in those with histology different from clear cells.

AB - Background: The aim of our study was to evaluate the efficacy and safety in unresectable or advanced renal carcinoma treated with sorafenib, in a situation closely similar to the everyday medical practice. Patients and Methods: One hundred and thirty-six patients have been treated with 400 mg b.i.d. of sorafenib administered orally until disease progression or unacceptable toxicity. They were either previously untreated or relapsed after one or more previous treatments with systemic therapy. Most of them had clear cell renal carcinoma (RCC), but other histological types such as papillary, chromophobe, Bellini ducts, sarcomatoid and mixed forms were also represented. Results: Overall disease control of 70.6% was achieved with 7.9% of partial remissions. Response was observed in the majority of patients with RCC, but also in some patients with non-clear cell RCC. Safety was acceptable, with the most common adverse events consisting of hand-foot skin reaction, cutaneous rash, diarrhoea, fatigue and hypertension. Conclusions: The results confirm previous ones reported in the literature concerning the efficacy and the safety of sorafenib as second-line treatment in patients with RCC. In addition, they disclose the hypothesis that sorafenib could be effective also in patients who underwent multiple previous treatments and in those with histology different from clear cells.

KW - Drug-related toxicity

KW - Multikinase inhibitor

KW - Renal cell cancer

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=43049120667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049120667&partnerID=8YFLogxK

U2 - 10.1159/000127387

DO - 10.1159/000127387

M3 - Article

C2 - 18418013

AN - SCOPUS:43049120667

VL - 73

SP - 204

EP - 209

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3-4

ER -